Acute vision loss after intravitreal injection of bevacizumab (Avastin) associated with ocular ischemic syndrome

Ophthalmologica

Volumn 224, Issue 2, 2010, Pages 86-89

  Huang, Zei Lun ^a   Lin, Kung Hung ^b   Lee, Yuan Chieh ^a   Sheu, Min Muh ^a   Tsai, Rong Kung ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b Buddhist Tzu Chi General Hospital   (Japan)

Author keywords

Bevacizumab; Diabetic rubeosis; Ocular ischemic syndrome

Indexed keywords

BEVACIZUMAB;

ADULT; ANAMNESIS; ARTICLE; CAROTID ARTERY OBSTRUCTION; CASE REPORT; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; INTRAOCULAR PRESSURE; IRIS RUBEOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; OCULAR ISCHEMIC SYNDROME; STROKE; VISUAL ACUITY; VISUAL IMPAIRMENT;

ACUTE DISEASE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLINDNESS; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS; ISCHEMIA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETINAL VESSELS; STROKE; SYNDROME; ULTRASONOGRAPHY, DOPPLER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 69049091118     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235726     Document Type: Article

References (15)

1. Rich RM, Rosenfeld PJ, Puliafito CA: Shortterm safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
2. Iliev ME, Domig D, Wolf-Schnurrbursh U: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054-1056.
3. Mason JO 3rd, Albert MA Jr, Mays A: Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006; 26: 839-841.
4. Amselem L, Montero J, Diaz-Llopis M: Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol 2007; 144: 122-124.
5. Shah MA, Ilson D, Kelsen DP: Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab- based therapy. J Clin Oncol 2005; 23: 2574-2576.
6. Dafer RM, Schneck M, Friberg TR: Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007; 22: 201-204.
7. Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349.
8. Rodrigues EB, Shiroma H, Meyer CH, Maia M, Farah ME: Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007; 85: 915-916.
9. Meyer CH, Mennel S, Hörle S, Schmidt JC: Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 169-170.
10. Mennel S, Callizo J, Schmidt JC, Meyer CH: Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin TM ) injections. Acta Ophthalmol Scand 2007; 85: 689-691.
11. Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT, Lin SG, Rauser ME, Kaiser PK: Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27: 541-551.
12. Verdenburg JJ, Desjardins A, Herndon JE 2nd: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-1259.
13. Kim JE, Mantravadi AV, Hur EY, Covert DJ: Short-term intraocular pressure changes immediately after intravitreal injections of anti- vascular endothelial growth factor agents. Am J Ophthalmol 2008; 146: 930-934.
14. Jager RD, Aiello LP, Patel SC, Cunningham ET: Risks of intravitreous injections: a comprehensive review. Retina 2004; 24: 676-698.
15. DeLeve LD, Wang X, Hu L: Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 2004; 287: 757-763.